ADAPY

0.03003.23%
HK

Helen Katrina Tayton-Martin

Co-Founder

Dr. Helen Katrina Tayton-Martin, Ph.D., MBA, was Chief Business & Strategy Officer of Adaptimmune Therapeutics plc from October 2022 to 2025. She is the Co-Founder of Adaptimmune Therapeutics plc and had been its Chief Business Officer since March 15, 2017 until October 2022. Dr. Tayton-Martin is responsible for optimizing the strategic and commercial opportunity for Adaptimmune's assets, leading business development and commercial activities. She served as Chief Operating Officer at Avidex Limited from 2008 to March 2017. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management and commercial planning and Partnerships, including the Adaptimmune's strategic Partnership with GSK. Dr. Tayton-Martin served as the Chief Operating Officer of Adaptimmune Therapeutics plc from July 2008 to March 15, 2017. She joined Adaptimmune from Avidex Limited (subsequently MediGene Ltd.) where she was responsible for commercial development of the soluble TCR programme in cancer and HIV therapy from 2005 to 2008. She served as an Executive Director of Adaptimmune Therapeutics plc since September 2011. She has experience within the Pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She served for Avidex/MediGene Ltd. and was responsible for commercial development of the increased affinity TCR engineering programme in cancer and HIV therapy. She served as an Independent Director of Trillium Therapeutics Inc. since October 1, 2017 until November 17, 2021. Dr. Tayton-Martin holds a PhD in Molecular Immunology from the University of Bristol, U.K. and an MBA from London Business School.

Positions